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Introduction: Over the last decades, treatment for rectal cancer has substantially improved
with development of new surgical options and treatment modalities. With the improvement
of  survival, functional outcome and quality of life are getting more attention.
Study objective: To provide an overview of current modalities in rectal cancer treatment, with
particular emphasis on functional outcomes and quality of life.
Results: Functional outcomes after rectal cancer treatment are inﬂuenced by patient and
tumor characteristics, surgical technique, the use of preoperative radiotherapy and the
method and level of anastomosis. Sphincter preserving surgery for low rectal cancer often
results in poor functional outcomes that impair quality of life, referred to as low anterior
resection syndrome. Abdominoperineal resection imposes the need for a permanent stoma
but  avoids the risk of this syndrome. Contrary to general belief, long-term quality of life in
patients with a permanent stoma is similar to those after sphincter preserving surgery for
low  rectal cancer.
Conclusion: All patients should be informed about the risks of treatment modalities. Decision
on  rectal cancer treatment should be individualized since not all patients may beneﬁt from
a  sphincter preserving surgery “at any price”. Non-resection treatment should be the future
focus to avoid the need of a permanent stoma and bowel dysfunction. Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. This©  2016 Sociedadeis  an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
 Study conducted at Faculty of Medicine, Porto University, Porto, Portugal.
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ttp://dx.doi.org/10.1016/j.jcol.2016.05.001
237-9363/© 2016 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Resultados  funcionais  e  qualidade  de  vida  após  tratamento  do  câncer
retal
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Preservac¸ão de esfíncter
Estratégia watch and wait
r  e  s  u  m  o
Introduc¸ão: Ao longo das últimas décadas, o tratamento do câncer retal melhorou sub-
stancialmente com o desenvolvimento de novas opc¸ões terapêuticas. Com a melhoria da
sobrevida, os resultados funcionais e a qualidade de vida são cada vez mais tidos em
considerac¸ão.
Objetivos do estudo: Rever as modalidades atuais de tratamento do câncer retal, com enfase
nos  resultados funcionais e qualidade de vida.
Resultados: Os resultados funcionais após tratamento para o câncer retal é inﬂuenciado
pelas características do doente, do tumor, da técnica cirúrgica, do uso de radioterapia
pré-cirúrgica e do método e nível da anastomose. A cirurgia poupadora de esfíncter do
câncer retal baixo resulta frequentemente em maus resultados funcionais que prejudicam
a  qualidade de vida, denominados síndrome da ressecc¸ão anterior baixa. A amputac¸ão
abdominoperitoneal impõe a necessidade de uma colostomia deﬁnitiva mas evita os riscos
de  resultados funcionais deﬁcitários. Contrariamente à crenc¸a geral, a qualidade de vida a
longo-prazo em doentes com colostomia deﬁnitiva é semelhante à qualidade de vida após
cirurgia poupadora de esfíncter do câncer retal baixo.
Conclusão: Todos os doentes devem ser informados sobre o risco das opc¸ões terapêuticas.
A  decisão do tratamento do câncer retal deve ser individualizada uma  vez que nem todos
os  doentes beneﬁciarão de uma cirurgia poupadora de esfíncter “a qualquer prec¸o”. A pos-
sibilidade de tratamento sem ressecc¸ão devem ser o foco futuro para evitar a necessidade
de  uma colostomia deﬁnitiva e disfunc¸ão gastrointestinal.
©  2016 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda. Este
e´  um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://creativecommons.org/Introduction
Colorectal cancer is the third most commonly diagnosed can-
cer worldwide. Almost 1.4 million new cases were diagnosed
and 693,900 deaths were estimated to occur in 2012, with about
55% of cases occurring in developed countries. In Europe, it
counts as the second most frequent malignancy and cause of
cancer death, with an estimated 447,000 new cases diagnosed
and 215,000 deaths occurring in 2012.1
Approximately 30% of colorectal cancer are diagnosed in
the rectum and around one third of rectal cancer (RC) are
located on its third distal part.2,3
Improvements in earlier detection of RC from screening
programs, reduction of risk factors and enhanced treatment
modalities resulted in increased survival rates over the last
decades.4,5
Treatment of RC had been primarily focused on onco-
logic outcome, with detailed assessment of survival and local
recurrence.6 Less attention has being given to functional out-
comes and quality of life (QoL). QoL is the personal perception
of the impact of illness or treatments on physical, psycholog-
ical and social well-being.7 Functional and QoL impairments
are frequent among patients treated for RC, predominantly in
patients with low RC.8 With the increasing number of patients
living with treatment effects,9 these factors get a more  signif-
icant role in decision making for RC treatment.The purpose of this study is to review current modalities
in RC treatment, particularly its impact on functional out-
comes and QoL. Therefore, a review of the medical literaturelicenses/by-nc-nd/4.0/).
was performed regarding these outcomes after operative and
non-operative management of RC.
Historical  background
Although main enhancements in treatment modalities of RC
were achieved over the last decades, surgery remains the
privileged form of treatment.3,10 Abdominoperineal resection
(APR), primarily described by Miles in 1908, was the ﬁrst step
given in modern era of RC surgery. This procedure consisted
of an en bloc rectal dissection with its lymphovascular sup-
ply in order to obtain a cylindrical specimen.11 The anterior
resection of the rectum, popularized by Dixon 40 years later,
proved to be successful in cancers of the middle and upper rec-
tum and was the ﬁrst surgical procedure to avoid a deﬁnitive
stoma. However, the creation of a safety 5 cm resection mar-
gin from the dentate line did not allow resection of the lower
rectum, where APR remained the only available option.12
Several works began to re-evaluate the effect of distal
resection margins (DRM) on oncologic outcome. Many  stud-
ies reported that a DRM of 1 cm or even smaller had no
negative impact on oncologic outcome.13 In fact, distal intra-
mural dissemination of RC is rarely observed and probably
linked to high grade tumors, where survival is mostly due
to metastatic spread rather than local recurrence.14,15 On the
other side, the importance of circumferential resection mar-
gin (CRM) was conﬁrmed in multiple works, with positive
CRM negatively inﬂuencing local recurrence and survival.16
Its surgical approach was achieved by the introduction of total
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esorectal excision (TME), a surgical technique in which RC
s removed with intact mesorectum, containing vasculature
nd lymphatic draining, en block. The mesorectum concept
as deﬁned by Heald et al. in 1980.6 TME  adoption decreased
RM positivity and local recurrence, improving survival rates
or RC patients.17,18 Nowadays, TME  is the primary form of
reatment for RC, with an overall 5-year survival up to 80%.19
Anterior resection of the rectum became a reality in low RC;
olerance for smaller DRM, implementation of TME and avail-
bility of circular stapling devices was followed by a signiﬁcant
ecrease of APR rates.20–22 Aside from oncologic outcome,
phincter preservation is now considered a sign of surgical
uality for RC patients.11
bdominoperineal  resection  and  anterior
esection  of  the  rectum
everal changes in indications for APR were observed after its
rst description. Progresses in APR technique since it was orig-
nally introduced and application of TME  led to a decrease in
ocal recurrence and mortality rates.23 Nevertheless, recent
rticles established that when comparing to low anterior
esection of the rectum (LAR), APR displayed worse oncological
utcomes. A 2009 pooled analysis of 5 European randomized
linical trials24 reported that APR had signiﬁcantly higher CRM
ositivity (10 vs 5%), higher recurrence rates (20 vs 11%), and
orse 5 years survival (59 vs 70%). Similar results were con-
istently found in other works.25,26 These reports have led to
he suggestion that outcomes after APR were inherently worse
ompared to LAR. However, these poorest outcomes following
PR could be due to tumor characteristics. Rectal tumors in
atients who  undergo APR appear to be less differentiated,
ore locally advanced and with a lower response to neo-
djuvant chemoradiotherapy (CRT).27,28 Chen et al.20 reported
igher rates of CRM positivity following APR, nonetheless,
fter adjustment for other covariates, survival rates were not
nﬂuenced by the type of surgery as an independent risk fac-
or. A recent study in Netherlands reported no differences in
RM positivity between APR and LAR.29 Therefore, similar out-
omes could be obtained with both surgical techniques, even
or locally advanced tumors.30
Selection of surgical procedure depends fundamentally of
he surgeon preference, individual characteristics and tumor
peciﬁcs. If radical resection is required in low rectum tumors,
he two main treatment options are LAR and APR. Although
phincter preservation is currently an important goal, APR
till remains the ﬁrst choice in cases of very low tumors with
phincter complex invasion or impaired preoperative state,
ith approximately 24% of patients requiring APR for primary
umoral resection.31
ow  anterior  resection  syndrome
owel function is a major issue after a sphincter preserving
urgery for low RC. Bowel dysfunction occurs in 30–70% of
atients after LAR and may reach up to 90% in some series.32–34
Most common symptoms include abdominal pain, urgency,
ecal incontinence, frequent bowel movements, incomplete;3 6(4):251–261 253
evacuation, dolorous, irregular and/or obstructed defecation,
and clustering.8,33,35 When low anastomoses are performed,
patients become more  predispose to develop these unpleasant
symptoms.8 This group of complaints constitutes a medical
condition entitled “low anterior resection syndrome” (LARS).36
Patients with previously damaged sphincters, compromised
continence or chronic diarrheal pathologies are more  prone
to develop this syndrome.37 Frequently, LARS develops shortly
after surgery, decreasing in a few months, with stability been
reached in the ﬁrst 2 years.32,35,38
Etiology of LARS is multifactorial. Causes may include
injury of pelvic ﬂoor muscles, reduced rectal capacity and
compliance, diminished internal anal sphincter tone and lack
of inhibitory recto-anal reﬂex. Posteriorly to LAR, lesion of
sphincters with impairment of anal pressures and low recov-
ery of recto-anal reﬂex is frequently observed.39
While some patients may recover almost normal bowel
function, others experience these disabilities permanently,
conditioning long-term QoL. In fact, LARS is tightly associ-
ated with QoL, with major effect in global health status, social
function and role function.32
Living  with  a  stoma
It is generally assumed by many  surgeons and patients that a
permanent colostomy results in worse long-term QoL when
compared to a sphincter preserving surgery that can avoid
the adverse impact of living with a permanent stoma. This
belief was a major reason to adopt LAR as the ﬁrst choice of
treatment for low RC.40,41
Due to this assumption, there is a lack of randomized clin-
ical trials comparing the impact in QoL of a colostomy after
APR or after a sphincter-preserving technique. Nevertheless,
the most recent reviews challenge that conviction.42–45
In a 2005 Cochrane review42 of 2412 patients from 25
studies, no differences were found in QoL between patients
undergoing APR or LAR. The authors referred that prospective
studies with larger samples and better designed were required
to clarify this question.
In 2007, a meta-analysis by Cornish et al.43 of 1443 patients
also stated that, concerning QoL, no signiﬁcant global dif-
ferences were identiﬁed between APR and LAR groups, with
patients having similar perception of general health. These
ﬁndings were consistently reported in larger, higher qual-
ity and with self-administered questionnaires studies. This
review also did not ﬁnd signiﬁcant differences regarding
impaired body image.
These data were supported by more  recent studies using
reliable and validated instruments for QOL assessment.44,46–48
Patients undergoing sphincter-saving ultra-low AR have
signiﬁcantly more  complications than APR. Fisher et al.49
reported that 20% of patients had to deal with a permanent
stoma due to failure of the sphincter preserving technique,
leading to a negative impact in QOL. This occurred more  com-
monly in older patients.Frequently impaired gastrointestinal function following a
sphincter-preserving surgery could equalize the need of per-
manent stoma.50 Bowel dysfunction frequently experienced
by patients undergoing a sphincter preserving surgery affects
j). 2 0254  j coloproctol (rio 
QoL, even when patients were well advised by their surgeons.
These patients may have raised preoperative expectations,
which ultimately results in a great frustration if they have
to live with such disabilities. Oppositely, patients undergoing
APR typically have lower outcome prospects. However, when
they realize that a fairly normal life is possible despite living
with a stoma, these patients may become more  satisﬁed.38
This may be the reason why patients undergoing AR or APR
have similar overall QoL.
A possible explanation to the fact that patients with
markedly impaired bowel function report a good QoL may be
due to the “response-shift phenomenon”: the gratefulness for
living without a stoma allegedly shifts patient’s global QoL
expectations.51
APR should be viewed as a possibility to consider and
not only an end-of-line treatment option in behalf of QoL
alone. This seems to be particularly true in older patients,
patients with low life expectancy or with major anorectal
dysfunction.49,52
Urogenital  function
In RC treatment, pelvic organs and nerves are very close to
the neoplasm. Damage to these structures can result not only
in bowel, but also sexual and urinary impairment. The lesion
severity on pelvic autonomic nerves may vary depending on
the surgical approach.53,54 Post-operatory urogenital function
were improved by the introduction of TME  technique and the
increasing knowledge of pelvic autonomic nerve pathways.6,18
Currently, less than 40% of patients present urinary malfunc-
tion, while 10–70% of patients display sexual impairment.53,55
Stress and overﬂow incontinence, urgency, incomplete
emptying of the bladder, increased frequency of void-
ing and lack of bladder fullness perception are the most
frequent complaints of patients. Male sexual dysfunction fre-
quently involves impaired ejaculation (20–60%) and impotence
(20–46%). Inability to ejaculate is often not reversible.54,55 In
women, information regarding sexual function is rare; how-
ever, patients may complain of worsened sexual function,
including problems with lubrication and dyspareunia.56,57
Sexual dysfunction may not only be due to physical factors
like nerve injury after surgery or radiation therapy.54,57,58 In
fact, other factors like poor body image,  depression, fatigue
and loss of independence may also play an important role in
sexual dysfunction.57
Restorative  methods
In order to overcome LARS symptoms, different strategies for
restorative methods focusing on the proximal aspect of the
anastomosis have been developed to improve rectal volume
and compliance.36
When compared to straight colorectal or coloanal anasto-
mosis, colonic j-pouch, colonic side-to-end anastomosis and
coloplasty are associated with lower stool frequency, incon-
tinence, urgency, and fragmented stool pattern. These data
are supported by a recent meta-analysis59 reporting colonic j
pouch, side-to-end coloanal or transverse coloplasty to have 1 6;3  6(4):251–261
similar functional outcomes, that are superior when com-
pared to straight anastomosis in the ﬁrst post operatory year.
However, there appears to be no signiﬁcant differences beyond
2 years. This long-term improvement could be explained by
the continued increase in neorectal volume and recovery of
anorectal reﬂexes and sphincter function following straight
anastomosis, that probably allows continued improvement of
compliance and function.60
Better functional results are obtained shortly after RC
surgery when a pouch is used if the anastomosis is within
3 and 5 cm from the anal verge. If a pouch is created in an
upper level, evacuation problems are more  likely to occur.36,61
When it is located higher than 7 cm from the anal verge, a
straight anastomosis should be performed from a functional
perspective.36 Since urgency, frequency and incontinence are
harder to manage than evacuation difﬁculties, the pouch
should also not be too small.36,61
The few works that addressed post-operative QoL between
restorative methods did not report signiﬁcant differences
between these techniques.59
Approach  techniques
Laparoscopic  surgery
Laparoscopic technique has been recently applied to TME  for
RC. Recent randomized clinical trials indicated that, when
compared to open surgery, this technique has no compromise
in oncologic outcomes, has similar complication rates and
advantages in earlier postoperative recovery with less blood
loss, rapid intestinal recovery, shorter hospital stay and lower
postoperative pain.62–66
With laparoscopic surgery allowing a better visualiza-
tion of the operative ﬁeld, this could contribute to a better
preservation of pelvic autonomic nerves, therefore reducing
genitourinary dysfunction following RC surgery.62
The United Kingdom Medical Research Council CLASSIC
trial67,68 is the only randomized clinical trial that com-
pared genitourinary functions between open and laparoscopic
surgery for RC. While no difference was found in terms of
bladder function, male patients had a tendency for worse sex-
ual functions after laparoscopic surgery. This would have a
stronger impact in sexually active male patients with large or
low RC, and could have implications when deciding the best
operative approach.67,68
However, more  recent prospective studies stated that nei-
ther laparoscopic nor open surgery appears to have superior
results regarding preservation of urinary or sexual func-
tion, although available data is limited.69 These results could
be explained by the continued increase in experience with
laparoscopic surgery.
It is unclear whether laparoscopic approach could offer
better QoL. When comparing different surgical approaches,
studies evaluating QoL have obvious disagreements. While
some studies reported a better QoL in both short and
long-term after laparoscopic surgery,66,70 others did not
ﬁnd any beneﬁts in long-term QoL following this surgi-
cal approach.71–73 In a multicenter randomized clinical trial
(COLOR II),74 there were no signiﬁcant differences in QoL
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etween these surgical approaches at 1, 6 or 12 months. Both
aparoscopic and open surgery impaired postoperative QoL,
ecovering gradually to preoperative levels overtime.
Since laparoscopic or open surgery might not present
ifferences in QoL, the previously described beneﬁts of laparo-
copic surgery like less blood loss, rapid intestinal recovery,
horter hospital stay and lower postoperative pain, could be
aken more  into account when selecting surgical approach for
C treatment.
obotic  surgery
obotic surgery has emerged during the last decade with
everal studies reporting comparable safety and feasibility
o laparoscopic surgery in RC surgery.75 When compared to
aparoscopic surgery, robotic surgery has the advantages of
roviding high-resolution 3D view, physiologic tremor reduc-
ion and articulating instruments.76
Despite being rarely evaluated, some studies have sug-
ested that robotic surgery could achieve better functional
utcomes, however, this is still unclear, as more  international
ulticenter randomized clinical trials are needed to deter-
ine these possible advantages.75
ew  sphincter  preserving  techniques
ntersphincteric  resection  (ISR)
SR was described in 1994 by Schiessel et al.77 A transanal
ivision of the rectum, with removal of entire or part of the
nternal anal sphincter, is performed after TME. This was only
ossible due to acceptable reduction of distal safety margins
o 1 cm.13
This extreme sphincter preserving surgery has been used
ver the last decades for patients with very low RC, who oth-
rwise had indication for APR with permanent colostomy.77,78
In T1-3 tumors located between 3 and 3.5 cm from the anal
erge, oncologic outcomes (both overall survival and 5-year
isease-free survival) does not appear to be adversely affected
y ISR, when compared to LAR or APR.79–81
Functional outcome is a major concern in ISR. LARS is fre-
uently observed after this technique; a 2012 meta-analysis
f 8 studies stated that 11–63% of patients reported fecal
ncontinence and 30–86% reported total continence. However,
uthors stated that functional outcomes are incompletely
eported and, when available, demonstrate wide variability.81
When compared to LAR, fecal continence is more  fre-
uently impaired after ISR. This is probably explained by a
igniﬁcant decrease of the postoperative sphincter resting
ressure.82 An estimated 40–85% of anal resting pressure is
ontributed by internal anal sphincter, playing a major role in
aintaining continence.83 However, both techniques appear
o result in comparable urgency and stool frequency.84
Performing only a partial excision82 and the construction
f a colonic j-pouch85,86 improves functional results, pre-
ominantly in the ﬁrst year after surgery. Preoperative CRT
igniﬁcantly impairs functional outcomes.87
Few works have addressed post-operative QoL after ISR
nd data is contradictory.81 Yong patients with early stages;3 6(4):251–261 255
RC (T1-2), who do not require preoperative radiotherapy (PRT)
and have good preoperative sphincter pressures, are the best
candidates for ISR.37,78 Patients should be informed about the
possible impairment of functional outcomes after ISR, par-
ticularly stool incontinence, and decide if dealing with such
conditions is preferable to live with a permanent stoma.
Anterior  Perineal  PlanE  For  ultra  low  Anterior  Resection  of
the rectum  (APPEAR)
Williams et al.88 initially described APPEAR technique in 2008
as an alternative method for very low rectal resection. It is
indicated for RC within 2–5 cm from the anal verge.89 This
technique uses an abdominal and a perineal approach, in
which a crescent shaped incision is made in the perineum,
between the vagina or the scrotum and the anal verge. This
allows a better access to the distal rectum for mobilization
when compared to the ultra-low AR and a better preservation
of the sphincter muscle when compared to ISR.37
The pilot study88 included 14 patients, 7 with rectal neo-
plasia. No local recurrences were reported, but one patient
developed systemic disease. Seven patients (50%) presented
anastomotic perineal ﬁstulae and, at 1-year follow-up, 5 (36%)
patients were not considered for ileostomy reversal. Three
patients (21%) developed transient sexual dysfunction but no
urological impairment was found. The authors also reported
that after perineal dissection, patients with RC had a median
Wexner continence score of 5 following ileostomy closure. No
signiﬁcant difference was observed in anorectal physiologic
testing or QOL.
In a more  recent study,90 no local recurrence was reported
and, after ostomy closure, the median Wexner score docu-
mented was 5.5.
More studies are needed for evaluation of this recent
technique, since there is a lack of studies on oncologic and
functional outcomes and QOL.
Transanal  Total  Mesorectal  Excision  (TaTME)
TaTME is a rectal natural oriﬁce transluminal endoscopic
surgery (NOTES). It consists of a transanal approach, usually
with transabdominal assistance. TaTME allows a better mobi-
lization of the distal rectum and sphincter preservation for
difﬁcult to reach distal RC, particularly in male patients with a
narrow pelvis and/or obesity where the abdominal approach
is challenging.91,92 Contrary to APPER technique, there is no
need to create a separate perineal wound.
Evidence suggests that TaTME is feasible and safe. A recent
systematic review of 26 studies reported adequate and repro-
ducible oncologic outcomes, with CRM positivity being equal
to those achieved in low AR and inferior to those achieved
in APR.93 A more  recent multicenter prospective study of 56
patients94 reported an average DRM of 10 mm and an average
CRM of 8 mm,  with R0 resection achieved in 53 patients (94.6%).
Twenty six per cent of patients had postoperative complica-
tions. Functional outcome was only accessed by this study,
with 28% (13) of patients reporting a fragmented stool pattern
and evacuation difﬁculty. The reported median Wexner score
for incontinence was 4 (3–12).
j). 2 0256  j coloproctol (rio 
The transanal approach can be performed with either
transanal endoscopic microsurgery (TEM) or transanal min-
imally invasive microsurgery (TAMIS). It appears that both
techniques offer similar resection quality.95,96
TaTME technique may be a promising alternative to con-
ventional low AR, but there is a necessity of further studies to
better evaluate oncological and functional outcomes, as well
as the impact on QoL.
Local  excision
In recent years, with improvements of screening programs
leading to early diagnosis of RC, more  attention is being paid
to local excision as an attractive alternative to radical trans-
abdominal resection. Local excision can be performed using
conventional transanal excision, TEM or the more  recently
described TAMIS.
Compared to the newer techniques, conventional transanal
excision has a reported lower resection quality and higher
local recurrence and mortality.96,97
In 1980, Buess et al.98 developed TEM, a minimally invasive
technique initially described for removal of adenomas that
were endoscopically unresectable, using speciﬁc instruments
and a rectoscope that offered high precision for transanal local
excision.
TEM can achieve rectal preservation for benign polyps and
early RC. It eliminates the need for a permanent colostomy
and is associated with lower morbidity and impact on func-
tional outcome and QoL than TME.99–101 The safety and
effectiveness of this technique is well documented, with
several studies reporting survival and local recurrence com-
parable to radical surgery in well selected cases.99,102–105
Nevertheless, oncologic outcomes of this technique still
remain a matter of study and debate.
TEM is an option to consider in patients with adenomas
not manageable through endoscopy or with favorable early
stage RC who  want to avoid radical resection of the rec-
tum and are willing to accept a possible higher risk of local
recurrence.89,106,107 It can also be recommended for patients
with advanced tumor unable to undergo radical surgery, as a
palliative treatment.89,106,107 Presently, the eligible proportion
of RC that could undergo local excision is small. This propor-
tion may increase with the combined use of CRT in carefully
selected cases.106
There is a concern that a prolonged use of a 40 mm diam-
eter operating scope could overstretch the anal sphincters
and cause postoperative impairment in fecal continence. In
fact, resting anal pressure is frequently reduced postopera-
tively, however this reduction is only temporary (likely to have
resolved by 3 months) and it does not appear to change con-
tinence scores.100,108–110
Several studies reported that TEM has a negative impact on
anorectal function and QoL, with patients complaining of fecal
incontinence, increased stool frequency, pain, ﬂatulence, sore
skin and embarrassment.111,112 These effects are also reported
to be temporary. Homps et al.112 analyzed 102 patients after
TEM for RC and reported that functional outcome and QoL
deterioration was worse after 6 weeks but returned to nor-
mal  levels at 12 weeks. Similar results were found by Lezoche 1 6;3  6(4):251–261
et al.,111 with bowel function returning to normal levels at 26
weeks.
Allaix et al.113 analyzed 93 patients who underwent TEM
after 5 years follow-up and reported that anorectal function
declined in the ﬁrst 3 months, returning to preoperative levels
12months after surgery. There was no difference in long-term
continence and QoL scores before and after surgery.
In a 41 patients prospective study by Cataldo et al.,108 no
differences were found in FISI (fecal incontinence severity
index) and FIOL (fecal incontinence QoL) scores, number of
bower movements per 24 h and urgency between preoperative
and 6 weeks after surgery.
Doornebush et al.100 and Planting et al.101 reported that
fecal incontinence QoL was improved after surgery in patients
with preoperative fecal incontinence. This could be due to
improved fecal continence after tumor excision in patients
that had diarrhea caused by a mucous producing tumor.
In the limited existing literature, it appears that QoL and
anorectal function may be impaired after TEM surgery, with
no long-term effect.
TEM has the disadvantage of a steep learning curve and ele-
vated costs of specialized instrumentation.114 In 2009, TAMIS
was developed as a feasible and low-cost alternative to TEM
for local excision of rectal lesions. This new technique uses
familiar laparoscopic instruments through a transanal multi-
channel single-port, a simple and easy to use device with low
equipment costs and minimal setup time.115
Both TEM and TAMIS have the same indications,95,116
however there is a lack of studies reporting functional and
oncologic outcomes of TAMIS for early RC and adenomas
resection. One study evaluating TAMIS functional outcome
after resection of rectal polyps reported functional outcomes
to be comparable to those obtained with TEM.117
Neoadjuvant  therapy
Regardless of the increasing development of surgical tech-
niques, it is now generally accepted as standard practice to use
a multimodal approach in RC treatment in order to achieve
optimal results. PRT signiﬁcantly reduces local recurrence
rates, improves local control and enables sphincter preserva-
tion in selected cases, however it does not appear to change
overall survival.118–120
Nevertheless, in addition to surgery, PRT is related with
an increased incidence and severity of bowel dysfunction,
with patients reporting more  fecal incontinence, urgency, and
higher stool frequency and evacuation disorders.56,118,121 It
is also associated with a diminished resting and squeeze
pressures in anorectal manometry.122
Chen et al.123 investigated health-related QOL in the Dutch
TME trial and reported that addition of PRT to TME  increases
the risk of major LARS score from 35 to 56%, with major LARS
being associated with reduced health related QoL. It has also
been shown that PRT increases the risk of sexual and urinary
dysfunction,124 further compromising QoL.118,121When associated to local excision techniques, PRT therapy
signiﬁcantly increases postoperative morbidity.125 In a Polish
multicenter trial,126 patients that undergone local excision
and PRT had similar anorectal functional outcomes compared
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o those observed in patients undergoing AR alone. The
uthors concluded that better functional outcomes achieved
y local excision could be compromised by PRT.
The mechanisms that could contribute to the adverse
mpact of radiotherapy on anorectal function are not yet com-
letely understood. Da Silva et al.127 observed that pelvic
rradiation increases collagen deposition and causes damage
o internal anal sphincter myenteric plexus. These effects
ould be responsible to the decrease of maximum anal resting
nd squeeze pressures and reduction of neorectum capacity,
ontributing to anorectal dysfunction.128,129
Presently, there is few available data on functional out-
omes after preoperative CRT for RC treatment, however it
ppears that both PRC and preoperative CRT have similar
norectal functional results130 and long term QoL.131
Both potential beneﬁts and risk of increased anorectal dys-
unctional after PRT should be considered when choosing the
ost adequate treatment option.
Wait-and-see  policy”,  the  next  step  in  rectal
ancer  treatment?
n select patients with complete tumor regression after CRT,
doption of a non-operative strategy could avoid a mutilating
urgery and its sequelae, resulting in better functional out-
omes and QoL.132
Approximately 15–20% of patients with locally advanced
C have a pathological complete response (pCR) after neoad-
uvant CRT, with no residual tumor observed in the resected
pecimen.133 pCR is found in a subgroup of patients with
linical complete response (cCP), in which residual tumor is
ot clinically detectable. However, there is a poor correlation
etween clinical and pathological responses, making it difﬁ-
ult to determine which patients with cCP also has pCR.134
Habr-Gama et al.135 was the ﬁrst to systematically evalu-
te the outcomes of a non-operative strategy in patients who
chieved cCR after CRT. The results obtained in this series were
mpressive, with no cancer-related death reported in a mean
7 months follow-up, suggesting that these patients had sim-
lar survival rates to patients who  had radical surgery after
RT and had pCR conﬁrmation. Other studies have supported
hese results.136,137
A more  recent study by Habr-Gamma et al.138 reported a
ustained complete response at 1 year in 57% of patients man-
ged non-operatively after CRT and, after a mean 56 months
ollow-up, 51% of patients were free of recurrence.
Despite remaining controversial and in an experimental
hase, results from the Habr-Gama series suggests that a
roup of selected patients with complete response after CRT
ould be managed with the wait-and-see approach, after eval-
ation of risks and beneﬁts with the patient.
onclusion
ver the last decades treatment for RC has improved with
evelopment of new surgical options and treatment modal-
ties. While oncologic outcome remains the primary goal in
C treatment, functional outcomes and QoL are getting more
ttention. If similar oncological outcomes are achieved for RC;3 6(4):251–261 257
treatment options, functional outcomes and QoL play a major
part when deciding for the most adequate treatment option
for each patient.
Functional outcomes after low RC treatment are inﬂuenced
by multiple factors, including patient and tumor characteris-
tics, surgical technique, the use of radio or chemotherapy and
the method and level of anastomosis.
Sphincter preserving surgery remains a priority and a mark
of surgical quality RC treatment, in part due the general belief
by both patients and surgeons that avoiding a permanent
colostomy would result in better long term QoL. However,
there is enough evidence to support that long-term QoL in
patients with a permanent stoma are similar to those after
sphincter preserving surgery for low RC. Patients should be
aware that sphincter preserving surgery for low RC often result
in poor functional outcomes that impairs QoL. Therefore,
depending on patient’s characteristics and personal prefer-
ences, decision should be individualized since not all patients
may beneﬁt from a sphincter preserving surgery “at any price”.
Postoperative bowel disabilities should always be taken into
account when surgery technique is selected and patients who
are not willing to live with such potential limitations should
consider undergoing a non-sphincter preserving surgery.
Local excision and non-operative treatments are starting
to get more  attention in carefully selected patients, in which
the need of a permanent stoma and bowel dysfunction could
be avoided, achieving better QoL. However, the “wait-and-see
policy” still remains in an experimental phase, requiring more
studies to better evaluate this approach.
Patients need to be clearly informed about all the treat-
ment options for low RC and its potential outcomes, including
the possibility of a non-surgical approach, so that patients
could have more  realistic expectations and be involved in the
decision making process.
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